Analysts’ Top Healthcare Picks: McKesson (MCK), Agios Pharma (AGIO)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on McKesson (MCK) and Agios Pharma (AGIO) with bullish sentiments.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
McKesson (MCK)
In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on McKesson, with a price target of $900.00. The company’s shares closed last Friday at $775.66.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
McKesson has an analyst consensus of Strong Buy, with a price target consensus of $946.91.
See today’s best-performing stocks on TipRanks >>
Agios Pharma (AGIO)
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Agios Pharma today and set a price target of $40.00. The company’s shares closed last Friday at $28.29, close to its 52-week low of $27.14.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Agios Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $39.20, implying a 35.4% upside from current levels. In a report issued on June 1, Truist Financial also maintained a Buy rating on the stock.
Read More on MCK:
Disclaimer & DisclosureReport an Issue
- McKesson Buy Rating Reaffirmed as GLP-1 Positioning Supports Outlook; $900 Price Target Maintained
- McKesson closes investment with Apollo Funds for minority interest in MMS
- The Week That Was, The Week Ahead: Macro and Markets, May 31
- Erin Wright Reiterates Buy on McKesson, Citing Durable Growth, Biosimilar Tailwinds, and AI-Driven Efficiency Supporting Higher FY27 Valuation Multiple
- McKesson price target lowered to $945 from $975 at Citi
